# Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

> **NCT04056897** · PHASE2 · COMPLETED · sponsor: **Biocad** · enrollment: 271 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BCD-132, 125 mg
- **DRUG:** Teriflunomide
- **DRUG:** Placebo
- **BIOLOGICAL:** BCD-132, 500 mg

## Key facts

- **NCT ID:** NCT04056897
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-07
- **Primary completion:** 2020-07-13
- **Final completion:** 2022-01-12
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056897, "Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04056897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*